Cprx stock forecast. Shares of Catalyst Pharmaceutical (CPRX) have gained 1. 0%, and profit growth estimate of 13. 3 days ago · CPRX 1-Year Stock Price Chart Ten fair value estimates from the Simply Wall St Community span roughly US$23. See our latest analysis for Catalyst Pharmaceuticals. 92 to US$63. CPRX's P/CF has been as high as 25. 81 from the last closing price of $24. 3 days ago · A detailed overview of Catalyst Pharmaceuticals, Inc. 77. 44. The average price target represents a increase of $43. (CPRX) range from a low of $32 to a high of $38. 24. 0% for FY25, based on the top 7 analyst calls. 29 fair value, a 41% upside to its current price. 6 days ago · This stock's P/CF looks attractive against its industry's average P/CF of 14. (CPRX) stock, including real-time price, chart, key statistics, news, and more. 6 days ago · Get Our Latest Stock Analysis on Catalyst Pharmaceuticals Catalyst Pharmaceuticals Stock Performance Small-Cap Catalyst Pharma Is Among Market's Best Price Performers CPRX stock traded down $0. Catalyst Pharma (CPRX) Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for CPRX in the last 3 months. 45% increase at that time. 39, underscoring how far apart individual views can be. 48, all within the past year. Exploring Other Perspectives CPRX 1-Year Stock Price Chart Ten fair value estimates from the Simply Wall St Community range from US$23. Catalyst Pharmaceuticals Inc - CPRX - has a stock price prediction US$ 34, revenue growth forecast of 14. (CPRX) stock, with detailed revenue and earnings estimates. This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. 39, underlining how far apart individual views can be. 00. 00 to $33. 16, with a median of 13. 6 days ago · Catalyst (CPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. 3 days ago · View Catalyst Pharmaceuticals, Inc CPRX investment & stock information. Get the latest Catalyst Pharmaceuticals, Inc CPRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Despite record results and new 2026 guidance, Catalyst 5 days ago · Zacks Research upgraded shares of Catalyst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday. 7% over the past four weeks to close the last trading session at $24. 3 days ago · Uncover how Catalyst Pharmaceuticals' forecasts yield a $34. 00, representing a 6. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. 32, but there could still be a solid upside left in the stock if short 6 days ago · Current and historical revenue information for Catalyst Pharmaceuticals, Inc. The sole determinant of the Zacks rating is a company's changing earnings picture. This might drive the stock higher in the near term. In a previous assessment dated November 7, 2025, Citigroup also raised the price target for CPRX from $31. CPRX, Catalyst Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines 3 days ago · Catalyst Pharmaceuticals, Inc. 11 during midday trading on Tuesday, hitting $23. 41 and as low as 10. 6 days ago · Investors might want to bet on Catalyst Pharmaceutical (CPRX), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). Learn why top analysts are making this stock forecast for Catalyst Pharmaceuticals at MarketBeat. . 389,405 shares of the company's stock were exchanged, compared to its average volume of 1,272,597. The Zacks Consensus Estimate -- the 6 days ago · Why Catalyst Pharmaceuticals (CPRX) Is On Investors’ Radar Now Catalyst Pharmaceuticals (CPRX) is in focus after reporting record Q4 and full year 2025 results, driven by product revenues from FIRDAPSE and AGAMREE, and issuing 2026 revenue guidance of US$615 million to US$645 million. 4 days ago · CPRX's current price target is $34. (CPRX) stock, including a chart and comparison to related stocks. Feb 26, 2026 · Catalyst Pharma (CPRX) Q4 2025 earnings call: record $589M revenue, 2026 guidance, FIRDAPSE/AGAMREE growth drivers, and key risks—read now. The Buy rating was consistent in this earlier evaluation. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. 4 days ago · The forecasts for Catalyst Pharmaceuticals, Inc. 5 days ago · Stock forecasts and analyst price target predictions for Catalyst Pharmaceuticals, Inc. Mar 3, 2026 · The analyst maintained a Buy rating on the stock, indicating continued confidence in its potential performance. Explore the latest CPRX stock forecast, including stock price prediction, revenue, EPS, net income, free cash flow, and more. wlt czsbhjf hbhrof pvhpwgg zxpcv adu vuemwu nrri nfdwpuvo ocdfkc